Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock

Chief Strategy Officer Jennifer Riley of Avalo Therapeutics (NASDAQ: AVTX) sold 2,655 shares of the company's common stock on August 11, 2026, according to a recent SEC filing. The sale amounted to $52,012, with shares sold at prices between $19.54 and $19.65 per share. The weighted average price for the transaction was $19.5903 per share.

The sale occurred following a 117% return on the stock over the past year, although InvestingPro analysis indicates the shares may be overvalued relative to their Fair Value estimate. After the sale, Riley directly beneficially owns 37,041 shares of Avalo Therapeutics common stock. Avalo Therapeutics recently received the inclusion in the Russell 2000 and 3000 indexes, a notable achievement for the company.

The stock's performance and strategic developments, including the inclusion in major indexes, are highlighted by recent analyst ratings. Cantor Fitzgerald reiterates an Overweight rating on the stock, while Leerink initiates coverage with an Outperform rating and a price target of $38.00. These developments, alongside positive Phase 2 data from Avalo's lead IL-1β-based therapy program, abdakibart, underscore the company's ongoing progress in the biotechnology sector.